Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-09-05
2006-09-05
Kifle, Bruck (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C540S495000
Reexamination Certificate
active
07101872
ABSTRACT:
This invention relates to a novel farnesylated dibenzodiazepinone, named ECO-04601, its pharmaceutically acceptable salts and derivatives, and to methods for obtaining such compounds. One method of obtaining the ECO-04601 compound is by cultivation of a novel strain ofMicromonosporasp., 046-ECO11; another method involves expression of biosynthetic pathway genes in transformed host cells. The present invention further relates toMicromonosporasp. strain 046-ECO11, to the use of ECO-04601 and its pharmaceutically acceptable salts and derivatives as pharmaceuticals, in particular to their use as inhibitors of cancer cell growth, bacterial cell growth, mammalian lipoxygenase, and to pharmaceutical compositions comprising ECO-04601 or a pharmaceutically acceptable salt or derivative thereof. Finally, the invention relates to novel polynucleotide sequences and their encoded proteins, which are involved in the biosynthesis of ECO-04601.
REFERENCES:
patent: 3854480 (1974-12-01), Zaffaroni
patent: 4452775 (1984-06-01), Kent
patent: 5039660 (1991-08-01), Leonard et al.
patent: 5393665 (1995-02-01), Fayerman et al.
patent: 5466590 (1995-11-01), Sariaslani et al.
patent: 5523288 (1996-06-01), Cohen et al.
patent: 5541181 (1996-07-01), Ohkuma et al.
patent: 5556772 (1996-09-01), Sorge et al.
patent: 5783561 (1998-07-01), Horwitz et al.
patent: 5830695 (1998-11-01), Serizawa et al.
patent: 6140306 (2000-10-01), Lambert, Jr. et al.
Berge, et al., “Pharmaceutical Salts”, Journal of Pharmaceutical Sciences (1977), V. 66, No. 1, pp. 1-19.
Goodfellow, “Suprageneric Classification of Actinomycetes”, Bergey's Manual of Systematic Bacteriology (1989), v. 4, pp. 2333-2339.
Embley and Stackebrandt, “The Molecular Phylogeny and Systematics of the Actinomycetes”, Annu. Rev. Microbiol. (1994), V. 48, pp. 257-289.
Zazopoulos, et al., “A Genomics-Guided Approach for Discovering and Expressing Cryptic Metabolic Pathways”, Nature Biotechnology (2003), V. 21, pp. 187-190.
Stryer, :Biochemistry 3rdEdition (1998), W.H. Freeman and Co., New York, pp. 752-754.
Altschul, et al., “Basic Local Alignment Search Tool”, Journal of Molecular Biology (1990, V. 215, No. 3, pp. 403-410.
Takagi, et al., “A Gene Cluster for the Mevalonate Pathway fromStreptomycessp. Strain CL190 ”, Journal of Bacteriology (2000), V. 182, No. 15, pp. 4153-4157.
Carrillo, et al., “The Multiple Sequence Alignment Problem in Biology”, Applied Math (1998), V. 48, No. 5, pp. 1073-1082.
Murakami, et al., “Thiostrepton-Induced Gene Expression inStreptomyces lividans”, Journal of Bacteriology (1989), V. 171, No. 3, pp. 1459-1466.
Thompson, et al., “Cloning of Antibiotic Resistance and Nutritional Genes inStreptomycetes”, Journal of Bacteriology (1982), V. 151, No. 2, pp. 668-677.
Hopwood, et al., “Plasmid and Phage Vectors for Gene Cloning and Analysis inStreptomyces”, Methods in Enzymology (1987), V. 153, pp. 116-166.
Nielson, et al., “Taq Extender PCR Additive for Improved Length, Yield, and Reliability of PCR Products”, Strategies (1994), V. 7, p. 27.
Matteucci, et al., “Synthesis of Deoxyoligonucleotides on a Polymer Support”, American Chemical Society (1981), V. 103, No. 11, pp. 3185-3191.
Gluzman, et al., “SV40-Transformed Simian Cells Support the Replication of Early SV40 Mutants”, Cell (1981), V. 23, No. 1, pp. 175-182.
Vaara, “Agents that Increase the Permeability of the Outer Membrane”, Microbiological Reviews (1992), V. 56, No. 3, pp. 395-411.
Tsubery, et al., “Structure-Function Studies of Polymyxin B Nonapeptide: Implications to Sensitization of Gram-Negative Bacteria”, Journal of Medical Chemistry (2000), V. 43, No. 16, pp. 3085-3092.
Carter, et al., “5-Lipoxygenase Inhibitory of Activity of Zileuton”, Journal of Pharmacology and Experimental Therapeutics (1991), V. 256, No. 3, pp. 929-937.
Safayhi, et al., “Concentration-Dependent Potentiating and Inhibitory Effects of Boswellia Extracts on 5-Lipoxygenase Product Formation in Stimulated PMNL”, Plant Medica (2000), V. 66, No. 2, pp. 110-113.
Workman, P., “UKCCR Guidelines for the Welfare of Animals in Experimental Neoplasia”, United Kingdom Coordinated Committee on Cancer Research, British Journal of Cancer 2ndEdition (1997), V. 77, pp. 1-10.
Premont, et al., “[3H] Norepinephrine Binding by Rat Glial Cells in Culture. Lack of Correlation between Binding and Adenylate Cyclase Activation”, Biochimica et Biophysica Acta (1975), V. 381, No. 2, pp. 368-376.
Dimitradou, et al., “Identification and Characterization of a New Cytotoxic Agent from Actinomycetes”, Poster Presentation Presented at the AACR Annual Meeting, Orlando, FL, Mar. 27 to 31, 2004.
Charan et al., Diazepinomicin, a new antimicrobial alkaloid from a marine Micromonospora sp. J. Nat Prod. Aug 2004;67(8):1431-3.
Igarashi, et al., “Revision of the Structure Assigned to the Antibiotic BU-4664L fromMicromonopora”, Journal of Antibiotics (2005), V. 58, No. 7, pp. 350-352.
Correction to p. 352. Igarashi, et al., “Revision of the Structure Assigned to the Antibiotic BU-4664L fromMicromonopora”, Journal of Antibiotics (2005), V. 58, No. 7, pp. 350-352.
Charan, et al., “A New Antimicrobial Alkaloid from a Micromonospora sp.”, Abstract and Figures from Poster Presentation #p:157 at the 44thAnnual Meeting of the American Society of Pharmacognosy, Chapel Hill, N.C., Jul. 12-16, 2003.
Bachmann Brian O.
Farnet Chris M.
McAlpine James B.
Piraee Mahmood
Zazopoulos Emmanuel
Ecopia Biosciences Inc.
Edwards Angell Palmer & & Dodge LLP
FitzGerald Mark J.
Kifle Bruck
Williams Kathleen M.
LandOfFree
Farnesyl dibenzodiazepinone, and processes for its production does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Farnesyl dibenzodiazepinone, and processes for its production, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Farnesyl dibenzodiazepinone, and processes for its production will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3592866